Quantum Biopharma Ltd. Files June 2025 6-K Report
Ticker: QNTM · Form: 6-K · Filed: Jun 13, 2025 · CIK: 1771885
| Field | Detail |
|---|---|
| Company | Quantum Biopharma Ltd. (QNTM) |
| Form Type | 6-K |
| Filed Date | Jun 13, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer, company-update
TL;DR
Quantum Biopharma (formerly FSD Pharma) filed its monthly 6-K, standard foreign issuer update.
AI Summary
Quantum Biopharma Ltd. filed a Form 6-K on June 13, 2025, reporting as a foreign private issuer for the month of June 2025. The company, formerly known as FSD Pharma Inc. until March 27, 2019, is incorporated in A6 and has its principal executive offices in Toronto, Ontario, Canada. Quantum Biopharma Ltd. operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding Quantum Biopharma Ltd.'s status as a foreign private issuer.
Risk Assessment
Risk Level: low — This filing is a routine report for a foreign private issuer and does not contain significant new financial or operational information.
Key Players & Entities
- Quantum Biopharma Ltd. (company) — Registrant
- FSD Pharma Inc. (company) — Former company name
- June 13, 2025 (date) — Filing date
- Toronto, Ontario, Canada (location) — Principal executive office location
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of June 2025.
What was Quantum Biopharma Ltd.'s former name and when did the change occur?
Quantum Biopharma Ltd.'s former name was FSD Pharma Inc., and the date of the name change was March 27, 2019.
Where are Quantum Biopharma Ltd.'s principal executive offices located?
The principal executive offices are located at 55 University Ave., Suite 1003, Toronto, Ontario M5J2H7, Canada.
Under which SEC Act is this filing made?
This filing is made under the Securities Exchange Act of 1934.
Does Quantum Biopharma Ltd. file annual reports under Form 20-F or Form 40-F?
Quantum Biopharma Ltd. indicates it files annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 13, 2025 regarding Quantum Biopharma Ltd. (QNTM).